| アブストラクト | Marketed pharmaceuticals are evaluated for safety by the US Food and Drug Administration (FDA) throughout the life cycle of the products. The FDA uses data from controlled clinical trials, from postmarketing case reports reported to the FDA's Adverse Event Reporting System, from epidemiological studies, and from registries to evaluate the safety of approved products. For some products, including some products used in dermatologic medicine, risks become apparent during the postmarketing period that require additional measures beyond product labeling and routine pharmacovigilance. The FDA continues to seek additional tools to assess risk, including pharmacogenomic biomarkers for adverse drug reactions and the use of large medical record and epidemiological databases for the systematic detection and characterization of drug-associated safety outcomes. |
|---|
| ジャーナル名 | Dermatologic therapy |
|---|
| Pubmed追加日 | 2009/05/21 |
|---|
| 投稿者 | Weaver, Joyce; Grenade, Lois La; Kwon, Hyon; Avigan, Mark |
|---|
| 組織名 | Division of Risk Management, Office of Surveillance and Epidemiology CDER, FDA,;Silver Spring, Maryland 20933, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/19453344/ |
|---|
